NCT00832572

Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy

A Double-blind, Placebo-controlled, Cross-over Study of Ranolazine in Patients With Coronary Artery Disease for the Treatment of Painful Polyneuropathy

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Gilead Sciences · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study was to determine whether ranolazine was effective in the treatment of neuropathic pain in patients with coronary artery disease. Eligibility required neurological examination by the study doctor and assessment of the patient's pain. Eligible participants were randomized to receive blinded study medication for a total of 12 weeks.

Conditions

• Coronary Artery Disease
• Pain
• Peripheral Nervous System Diseases
• Polyneuropathy

Interventions

Type	Name	Description
DRUG	Ranolazine	Ranolazine ER tablet administered orally for 6 weeks (500 mg twice a day for 3 weeks, followed by either 500 mg or 1000 mg twice a day for 3 weeks).
DRUG	Placebo	Placebo to match ranolazine administered twice a day for 6 weeks

Timeline

• Start date: 2009-01-01
• Primary completion: 2009-06-01
• Completion: 2009-06-01
• First posted: 2009-01-30
• Last updated: 2014-06-30
• Results posted: 2014-06-30

Locations

1 site across 1 country: United States